Benzinga | Jan 26, 2021 07:03AM EST

Stifel Upgrades Allogene Therapeutics to Buy, Raises Price Target to $43

Stifel analyst Benjamin Burnett upgrades Allogene Therapeutics (NASDAQ:ALLO) from Hold to Buy and raises the price target from $33 to $43.